This list is an analysis based on recent market events. It's not an investment recommendation.
About
Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California. On March 5, 2025, Cutera, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
The current price of TJ9.F is €16.84 EUR — it has decreased by -4.1% in the past 24 hours. Watch Cityvarasto Oyj stock price performance more closely on the chart.
What is Cityvarasto Oyj stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cityvarasto Oyj stocks are traded under the ticker TJ9.F.
When is the next Cityvarasto Oyj earnings date?▼
Cityvarasto Oyj is going to release the next earnings report on June 03, 2026.
What were Cityvarasto Oyj earnings last quarter?▼
TJ9.F earnings for the last quarter are 0.14 EUR per share, whereas the estimation was 0.14 EUR resulting in a +0% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Cityvarasto Oyj revenue for the last year?▼
Cityvarasto Oyj revenue for the last year amounts to 195.49M EUR.
What is Cityvarasto Oyj net income for the last year?▼
TJ9.F net income for the last year is -149.98M EUR.
How many employees does Cityvarasto Oyj have?▼
As of April 06, 2026, the company has 430 employees.
In which sector is Cityvarasto Oyj located?▼
Cityvarasto Oyj operates in the Health Care sector.
When did Cityvarasto Oyj complete a stock split?▼
Cityvarasto Oyj has not had any recent stock splits.